IGF-1 LR3 appears in the literature in contexts that must be kept distinct: molecular research, preclinical models, possible clinical studies and commercial products. This guide explains the terminology and limitations without dosing, reconstitution or administration instructions.
- Declared classification: Modified IGF-1 protein analogue
- Category: Endocrine & Growth Factor Research
- Catalogue presentations: 1 mg
- Status: research use only; availability is confirmed on enquiry
What research examines about IGF-1 LR3
IGF-1 LR3 is a modified IGF-1 analogue designed with an extended sequence and altered affinity for IGF-binding proteins. It is investigated in models of proliferation, differentiation and cellular signalling.
A mention in a scientific paper describes the molecule or model evaluated in that study. It does not automatically confirm the identity, purity, quantity, sterility or suitability of a commercial vial.
Investigated mechanism
Research examines activation of the IGF-1 receptor and associated intracellular pathways, such as PI3K/AKT and MAPK, in controlled experimental systems.
Responsible interpretation starts with the species, experimental system, comparator, method and endpoint. In-vitro findings, animal evidence and human-study results are not interchangeable.
How strong is the evidence?
Proliferative activity requires strict assessment of the model and risks. Laboratory data do not constitute a recommendation for personal use.
PeptidaLab does not turn preliminary results into personal promises. Where an authorised medicine uses a similar active substance, that authorisation applies to the specific product, manufacturer, indication and regulated supply chain—not to every material carrying the same name.
What should be verified for the batch?
A useful dossier links the vial unambiguously to its batch number, declared identity, analytical method, quantity, analysis date, issuing laboratory, storage conditions and chain of custody. HPLC and mass spectrometry can answer different questions; no isolated percentage establishes every product characteristic.
Associated catalogue pages
Frequently asked questions
What is IGF-1 LR3?
IGF-1 LR3 is listed in the catalogue as modified igf-1 protein analogue. That classification describes a research context, not a medical indication.
Which IGF-1 LR3 presentations are listed?
The catalogue lists: 1 mg. Commercial availability remains blocked pending legal and documentary review.
Is IGF-1 LR3 approved for human use?
This page describes only the scientific context of an RUO material. A publication about a molecule does not authorise the catalogue product for use in humans.
Method, sources and limitations
This material was written originally and reviewed to distinguish preclinical findings, human studies and commercial status. For legislation and authorisation, consult Directive 2001/83/EC, the EMA and relevant primary scientific literature.
For research use only (RUO). Not for use in humans. This article is not medical or legal advice and provides no instructions for use.